Dr Michelle Bradney: Ledger

Stories naming Dr Michelle Bradney. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Role	Organisation	Sources
Chief Operating Officer	OccuRx	Startup Daily, Brandon BioCatalyst portfolio, Brandon Capital portfolio

Unnamed stage $16m

$16m cash injection to progress first-in-class therapy for inflammation and fibrosis

Australian biotech OccuRx secured $16 million co-led by Brandon BioCatalyst and Uniseed, including a CUREator grant, to advance its oral anti-fibrosis therapy into kidney disease trials; two executives also joined.

Brandon Capital portfolio 5 Sep 2022 OccuRx Brandon Capital CERTA Therapeutics CSIRO Mana Communications The University of Queensland The University of Sydney University of Melbourne University of New South Wales Brandon BioCatalyst Medical Research Future Fund Uniseed UniSuper Professor Darren Kelly Dr Gareth Lewis Dr Michelle Bradney

Also Brandon BioCatalyst portfolio·Startup Daily

Dr Michelle Bradney

Roles

Coverage

$16m cash injection to progress first-in-class therapy for inflammation and fibrosis